Asset Management One Co. Ltd. Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Asset Management One Co. Ltd. raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 67,953 shares of the biopharmaceutical company's stock after buying an additional 2,257 shares during the period. Asset Management One Co. Ltd. owned about 0.05% of Alnylam Pharmaceuticals worth $18,689,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Allspring Global Investments Holdings LLC increased its holdings in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 143 shares during the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of Alnylam Pharmaceuticals by 32.3% during the 1st quarter. Commonwealth Equity Services LLC now owns 5,594 shares of the biopharmaceutical company's stock valued at $836,000 after purchasing an additional 1,365 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Alnylam Pharmaceuticals by 63.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 62,415 shares of the biopharmaceutical company's stock valued at $9,328,000 after purchasing an additional 24,228 shares during the last quarter. Janney Montgomery Scott LLC boosted its holdings in Alnylam Pharmaceuticals by 47.4% in the first quarter. Janney Montgomery Scott LLC now owns 2,775 shares of the biopharmaceutical company's stock worth $415,000 after purchasing an additional 892 shares in the last quarter. Finally, Nordea Investment Management AB increased its position in Alnylam Pharmaceuticals by 3.3% during the first quarter. Nordea Investment Management AB now owns 8,980 shares of the biopharmaceutical company's stock worth $1,365,000 after buying an additional 290 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Up 2.7 %

Shares of ALNY stock traded up $7.17 on Wednesday, hitting $272.46. The company had a trading volume of 798,002 shares, compared to its average volume of 870,943. The firm has a market cap of $35.14 billion, a P/E ratio of -101.26 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The stock's 50-day moving average is $274.33 and its two-hundred day moving average is $228.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts' expectations of $532.91 million. The business's quarterly revenue was down 33.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.15 EPS. On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on ALNY. Chardan Capital reaffirmed a "buy" rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Canaccord Genuity Group boosted their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a research note on Friday, November 1st. Citigroup increased their price target on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a "buy" rating in a research report on Friday, August 2nd. Royal Bank of Canada reissued an "outperform" rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Finally, Scotiabank increased their price objective on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a "sector outperform" rating in a report on Friday, November 1st. Six research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $294.50.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the firm's stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company's stock, valued at $20,563,480. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.